Giulia Collatuzzo1, Giovanni Visci1, Francesco S Violante1, Stefano Porru2, Gianluca Spiteri3, Maria Grazia Lourdes Monaco3, Francesca Larese Fillon4, Corrado Negro4, Christian Janke5, Noemi Castelletti5, Giuseppe De Palma6, Emanuele Sansone6, Dana Mates7, Silvia Teodorescu7, Eleonóra Fabiánová8, Jana Bérešová9, Luigi Vimercati10, Silvio Tafuri10, Mahsa Abedini1, Giorgia Ditano1, Shuffield S Asafo1, Paolo Boffetta1,11. 1. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 2. Section of Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. 3. Clinical Unit of Occupational Medicine, University Hospital of Verona, Verona, Italy. 4. Unit of Occupational Medicine, University of Trieste, Trieste, Italy. 5. Division of Infectious Diseases and Tropical Medicine, Ludwig Maximilian University (LMU) Klinikum, Munich, Germany. 6. Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy. 7. National Institute of Public Health, Bucharest, Romania. 8. Occupational Health Department, Regional Authority of Public Health, Banská Bystrica, Slovakia. 9. Epidemiology Department, Regional Authority of Public Health, Banská Bystrica, Slovakia. 10. Interdisciplinary Department of Medicine, University of Bari, Bari, Italy. 11. Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, United States.
Abstract
Background: The duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs). Methods: We analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1st dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses. Results: A 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels. Conclusions: Female gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.
Background: The duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs). Methods: We analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1st dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses. Results: A 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels. Conclusions: Female gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups.
Authors: Saman Saadat; Zahra Rikhtegaran Tehrani; James Logue; Michelle Newman; Matthew B Frieman; Anthony D Harris; Mohammad M Sajadi Journal: JAMA Date: 2021-04-13 Impact factor: 56.272
Authors: Yunkai Yu; Dominic Esposito; Zhigang Kang; Jianming Lu; Alan T Remaley; Valeria De Giorgi; Leonard N Chen; Kamille West; Liang Cao Journal: Sci Rep Date: 2022-02-16 Impact factor: 4.996
Authors: Xinxue Liu; Robert H Shaw; Arabella S V Stuart; Melanie Greenland; Parvinder K Aley; Nick J Andrews; J Claire Cameron; Sue Charlton; Elizabeth A Clutterbuck; Andrea M Collins; Tanya Dinesh; Anna England; Saul N Faust; Daniela M Ferreira; Adam Finn; Christopher A Green; Bassam Hallis; Paul T Heath; Helen Hill; Teresa Lambe; Rajeka Lazarus; Vincenzo Libri; Fei Long; Yama F Mujadidi; Emma L Plested; Samuel Provstgaard-Morys; Maheshi N Ramasamy; Mary Ramsay; Robert C Read; Hannah Robinson; Nisha Singh; David P J Turner; Paul J Turner; Laura L Walker; Rachel White; Jonathan S Nguyen-Van-Tam; Matthew D Snape Journal: Lancet Date: 2021-08-06 Impact factor: 79.321